CN1250284C - 甲型肝炎灭活疫苗 - Google Patents
甲型肝炎灭活疫苗 Download PDFInfo
- Publication number
- CN1250284C CN1250284C CN 02133927 CN02133927A CN1250284C CN 1250284 C CN1250284 C CN 1250284C CN 02133927 CN02133927 CN 02133927 CN 02133927 A CN02133927 A CN 02133927A CN 1250284 C CN1250284 C CN 1250284C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- virus
- phosphate
- inactivated vaccine
- nacl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000005252 hepatitis A Diseases 0.000 title claims abstract description 26
- 229940031551 inactivated vaccine Drugs 0.000 title claims abstract description 26
- 241000709721 Hepatovirus A Species 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000700605 Viruses Species 0.000 claims abstract description 11
- 101710163270 Nuclease Proteins 0.000 claims abstract description 8
- 230000029087 digestion Effects 0.000 claims abstract description 8
- 229920002271 DEAE-Sepharose Polymers 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 40
- 239000011780 sodium chloride Substances 0.000 claims description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 claims description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 229940061334 2-phenylphenol Drugs 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000009849 deactivation Effects 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000011536 extraction buffer Substances 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 235000010292 orthophenyl phenol Nutrition 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- 238000002525 ultrasonication Methods 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 150000003384 small molecules Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 230000000366 juvenile effect Effects 0.000 description 29
- 229960005486 vaccine Drugs 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 230000008676 import Effects 0.000 description 5
- 238000012207 quantitative assay Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940036131 hepatitis a immunoglobulin Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012205 qualitative assay Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
分组 | 抗原含量 | 接种人数 | 接种程序(月) | 采血日期(月) |
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 640ELU/1.0ml320ELU/0.5ml1280ELU/1.0ml640ELU/0.5ml720ELU/0.5mll440ELU/1.0ml | 107981311316975 | 0、60、60、60、60、60、6 | 1、6、71、6、71、6、71、6、71、6、71、6、7 |
疫苗分组 | 男女性别比 |
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 70∶37(1∶0.53)53∶45(1∶0.85)75∶56(1∶0.75)81∶50(1∶0.62)35∶34(1∶0.97)49∶26(1∶0.53) |
合计 | 363∶248(1∶0.68) |
年龄组(岁) | 疫苗组 | ||
全量少儿组N=107 | 半量少儿组N=98 | 少儿对照组N=69 | |
5678910111213 | 34366153013 | 41751233 | 10301721 |
平均 | 9.7 | 8.9 | 9.2 |
年龄组(岁) | 疫苗组 | ||
全量成人组N=131 | 半量成人组N=131 | 成人对照组N=75 | |
151617181920 | 236543531 | 7175635133 | 635322 |
平均 | 17.2 | 17.3 | 17.4 |
组别 | 免前(接种) | 免后一月 | 免后六月 | 免后七月 |
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 1071071311316975 | 97911201285672 | 10578119704650 | 991031191116571 |
分组 | 人数 | ≤37℃ | 37.1℃~37.5℃ | 37.6℃~40℃ | ||||||
24 | 48 | 72 | 24 | 48 | 72 | 24 | 48 | 72 | ||
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 107981311316975 | 107981221306974 | 107981231306974 | 107981261306974 | 009101 | 008101 | 005101 | 000000 | 000000 | 000000 |
分组 | 人数 | ≤37℃ | 37.1 | ℃~37.5℃ | 37.6℃~40℃ | |||||
24 | 48 | 72 | 24 | 48 | 72 | 24 | 48 | 72 | ||
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 107981311316975 | 106971301316975 | 107971301316975 | 106971311316975 | 111000 | 111000 | 110000 | 000000 | 000000 | 000000 |
分组 | 抗体阳转率%(月) | ||
1 | 6 | 7 | |
全量少儿组半量少儿组全量成人组半量成人组少儿对照组成人对照组 | 94.8(92/97)91.2(83/91)96.7(116/120)92.2(118/128)82.1(46/56)90.3(65/72) | 99.0(104/105)98.7(77/78)100.0(119/119)100.0(70/70)95.6(44/46)100.0(50/50) | 100.0(99/99)100.0(103/103)100.0(119/119)100.0(111/111)100.0(65/65)100.0(71/71) |
免后时间 | 测定人数 | 抗体水平mIU/ml | ||||
<200 | 200~1000 | >1000 | 几何平均值(GMT) | 95%可信限 | ||
全量少儿组 | ||||||
一月六月七月 | 282828 | 1 | 1971 | 82127 | 758.62951.210471.2 | 446.7~1288.21737.8~5011.97762.5~14125.4 |
半量少儿组 | ||||||
一月六月七月 | 282828 | 1292 | 171926 | 1778.22344.24786.3 | 1096.5~2884.01412.5~3890.53162.3~7244.4 | |
少儿对照组 | ||||||
一月六月七月 | 282828 | 106 | 12174 | 6524 | 457.1478.63090.3 | 275.4~758.6323.6~707.91995.3~4786.3 |
免后时间 | 测定人数 | 抗体水平mIU/ml | ||||
<200 | 200~1000 | >1000 | 几何平均值(GMT) | 95%可信限 | ||
全量成人组 | ||||||
一月六月七月 | 282828 | 1 | 651 | 212327 | 3630.82455.712302.7 | 2089.3~6309.61548.8~3890.58079.6~17378.0 |
半量成人组 | ||||||
一月六月七月 | 282828 | 4 | 1261 | 122227 | 977.22344.27762.5 | 537.0~1778.31584.9~3467.45495.4~10964.8 |
成人对照组 | ||||||
一月六月七月 | 282828 | 22 | 14233 | 12325 | 1380.4501.23388.4 | 446.7~1288.2331.1~758.62398.8~4786.3 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02133927 CN1250284C (zh) | 2002-10-17 | 2002-10-17 | 甲型肝炎灭活疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02133927 CN1250284C (zh) | 2002-10-17 | 2002-10-17 | 甲型肝炎灭活疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1490050A CN1490050A (zh) | 2004-04-21 |
CN1250284C true CN1250284C (zh) | 2006-04-12 |
Family
ID=34145717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02133927 Expired - Lifetime CN1250284C (zh) | 2002-10-17 | 2002-10-17 | 甲型肝炎灭活疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1250284C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102018958B (zh) * | 2009-09-11 | 2012-11-07 | 辽宁依生生物制药有限公司 | 去除疫苗制品中杂蛋白及宿主dna的方法 |
CN102058882B (zh) * | 2010-12-28 | 2012-12-26 | 深圳康泰生物制品股份有限公司 | 一种制备甲型肝炎灭活疫苗的方法 |
CN104306960A (zh) * | 2014-09-24 | 2015-01-28 | 郭和友 | 一种利用切割酶治疗病毒及癌症方法 |
CN104306961A (zh) * | 2014-10-05 | 2015-01-28 | 郭和友 | 利用切割酶清除潜伏休眠病毒或细菌方法 |
CN104306962A (zh) * | 2014-10-05 | 2015-01-28 | 郭和友 | 利用切割酶切割病毒转录酶方法 |
CN112143693A (zh) * | 2019-06-28 | 2020-12-29 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
-
2002
- 2002-10-17 CN CN 02133927 patent/CN1250284C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1490050A (zh) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101897963B (zh) | 一种手足口病病毒疫苗 | |
CN101695570B (zh) | 一种手足口病单、双价灭活疫苗及其制备方法 | |
CN105963692B (zh) | 一种预防手足口病的联合疫苗 | |
CN103386126B (zh) | 一种含肠道病毒抗原的多价免疫原性组合物 | |
CN109689862B (zh) | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 | |
CN1250284C (zh) | 甲型肝炎灭活疫苗 | |
CN1712068A (zh) | 二倍体细胞狂犬疫苗及纯化狂犬疫苗,剂型冻干及水针 | |
CN1958070A (zh) | 抗猪传染性胃肠炎、猪流行性腹泻、猪轮状病毒三联高免免疫球蛋白 | |
CN106075423B (zh) | 一种预防手足口病的联合疫苗 | |
CN105999256B (zh) | 一种预防手足口病的联合疫苗 | |
CN1884571A (zh) | 从石蒜属植物中提取多糖的工艺方法 | |
CN113278067B (zh) | 一种新型冠状病毒猪源性免疫球蛋白的制备方法 | |
CN110917344B (zh) | 一种液体疫苗组合物及其应用 | |
CN113813291A (zh) | 一种动物药材冻干粉的制备方法 | |
CN111053898A (zh) | 一种疫苗组合物及其应用 | |
CN102174477B (zh) | 甲型肝炎病毒株sh及其二倍体细胞适应方法 | |
CN1216985C (zh) | 甲型肝炎病毒毒株,制备甲肝灭活疫苗的方法及所得疫苗 | |
CN101306199A (zh) | 生产和纯化甲型肝炎灭活疫苗的方法 | |
CN1112934C (zh) | 流行性出血热传代细胞多价纯化疫苗 | |
CN1305526C (zh) | 乙型脑炎病毒裂解疫苗及其制备方法 | |
CN102335198B (zh) | 一种抗森林脑炎病毒马血清的生产方法 | |
CN1314449C (zh) | 乙型脑炎病毒疫苗和脑膜炎球菌结合疫苗组成的联合疫苗 | |
CN1616654A (zh) | 一种sars病毒的灭活及纯化方法以及制备含有所述灭活病毒疫苗的方法及所述疫苗 | |
CN1695736A (zh) | 乙型脑炎病毒疫苗及其制备方法 | |
CN104694486B (zh) | 一种二联手足口病灭活疫苗及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KUNMING SHANGCHENG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: MEDICAL BIOLOGY INST., CHINESE ACADEMY OF MEDICAL SCIENCES Effective date: 20100723 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650118 NO.379, JIAOLING ROAD, KUNMING CITY, YUNNAN PROVINCE TO: 650118 ROOM 503, BUILDING A2, ERQI, STATE COLLEGE SCIENCE PARK, KUNMING CITY HIGH-TECH ZONE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100723 Address after: 650118 A2 building 503, National University Science Park, Kunming hi tech Zone, 2 Patentee after: Kunming Cheng Cheng Biotechnology Co.,Ltd. Address before: Jiao Ling Road 650118 Yunnan city of Kunming Province, No. 379 Patentee before: INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES |
|
ASS | Succession or assignment of patent right |
Owner name: KUNMING SHENGFEI BIO-PHARMACEUTICAL TECHNOLOGY CO. Free format text: FORMER OWNER: KUNMING SHANGCHENG BIOTECHNOLOGY CO., LTD. Effective date: 20100825 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650118 ROOM 503, BUILDING A2, PHASE 2, NATIONAL UNIVERSITY SCIENCE AND TECHNOLOGY PARK, KUNMING HIGH-TECH. ZONE TO: 650118 ROOM 501, BUILDING A2, PHASE 2, NATIONAL UNIVERSITY SCIENCE AND TECHNOLOGY PARK, KUNMING HIGH-TECH. ZONE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100825 Address after: 650118 A2 building 501, National University Science Park, Kunming hi tech Zone, 2 Patentee after: Kunming Sheng Fei biological medicine technology Co.,Ltd. Address before: 650118 A2 building 503, National University Science Park, Kunming hi tech Zone, 2 Patentee before: Kunming Cheng Cheng Biotechnology Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatitis A inactivated vaccine Effective date of registration: 20101227 Granted publication date: 20060412 Pledgee: Pudong Shanghai Development Bank Limited by Share Ltd. Kunming branch Pledgor: Kunming Sheng Fei biological medicine technology Co.,Ltd. Registration number: 2010990001025 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Inactivated Hepatitis A Vaccine Effective date of registration: 20101227 Granted publication date: 20060412 Pledgee: Pudong Shanghai Development Bank Limited by Share Ltd. Kunming branch Pledgor: Kunming Sheng Fei biological medicine technology Co.,Ltd. Registration number: 2010990001025 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130304 Granted publication date: 20060412 Pledgee: Pudong Shanghai Development Bank Limited by Share Ltd. Kunming branch Pledgor: Kunming Sheng Fei biological medicine technology Co.,Ltd. Registration number: 2010990001025 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU CONVAC BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: KUNMING SHENGFEI BIOMEDICAL TECHNOLOGY CO., LTD. Effective date: 20130516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: KUNMING, YUNNAN PROVINCE TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130516 Address after: 225300 drug city, Taizhou hi tech Zone, Jiangsu Province Patentee after: JIANGSU CONVAC BIO-TECHNOLOGY Co.,Ltd. Address before: Room 501, building A2, 2, National University Science Park, Kunming hi tech Zone Patentee before: Kunming Sheng Fei biological medicine technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180517 Address after: No. 819, drug City Avenue, Taizhou, Jiangsu Province, Jiangsu Patentee after: AIMEI CONVAC BIO-PHARMACY (JIANGSU) Co.,Ltd. Address before: 225300 drug city road, Jiangsu medical and Technological Development Zone, Taizhou Patentee before: JIANGSU CONVAC BIO-TECHNOLOGY Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060412 |